NBIX — Neurocrine Biosciences, Inc.

Is NBIX overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Drug Manufacturers - Specialty & Generic

Oversold As of November 17, 2026

Neurocrine Biosciences, Inc. (NBIX) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Drug Manufacturers - Specialty & Generic) last closed at $165.31. The rating moved from Neutral to Oversold on November 17, 2026.

See all oversold Healthcare stocks →

AI analysis

Neurocrine Biosciences combines a cash-generating marketed franchise with an active specialty pipeline and optionality for partnerships or M&A. Near-term performance is likely to track broader defensive-healthcare flows and company-specific clinical/regulatory milestones. Key drivers include sustained prescription growth for existing products, successful pipeline progress, and disciplined business development; principal risks are clinical/regulatory setbacks, reimbursement pressures, and competitive dynamics.

Key factors

  • Established commercial revenue stream from marketed neurology products providing cash flow and margin support
  • Pipeline assets in specialty CNS and endocrine/rare-disease areas with potential mid-term revenue catalysts
  • Favorable sector flows into large-cap pharma/defensive healthcare names supporting relative share stability
  • Potential M&A or partnership optionality given industry trend of large-cap pharma licensing specialty franchises
  • Shift in distributor and specialty pharmacy dynamics could sustain prescription flow for chronic injectable and specialty therapies
  • Prudent balance sheet and ability to fund R&D and business development activities (supports execution on pipeline)

Risks

  • Clinical trial setbacks or negative readouts for pipeline assets that could materially reduce growth prospects
  • Regulatory or labeling risks from FDA review processes, impacting approvals or launch timelines
  • Pricing and reimbursement pressure, including indirect effects from Medicare Advantage program integrity changes
  • Competition from other therapies or new entrants that could erode market share for marketed products
  • Execution risk on commercial expansion, supply chain disruptions, or failure to secure strategic partnerships
  • Valuation sensitivity and market volatility during earnings season or sector rotation that could compress multiple

Latest MarketMoodz coverage

See today's live rating, score and targets

Members see the live hourly rating for NBIX — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.